Medicare Enrolled
Dr. Alla Khalfin, D.O.
Endocrinology · Syosset, NY
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Khalfin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Khalfin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Khalfin
Dr. Alla Khalfin is an endocrinology specialist in Syosset, NY, with 18 years of NPI registration. Based on federal Medicare data, Dr. Khalfin performed 5,584 Medicare services across 1,287 unique beneficiaries.
Between the years covered by Open Payments, Dr. Khalfin received a total of $56,101 from 62 pharmaceutical and/or device companies across 1095 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Khalfin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 13% volume in NY
$56,101 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,584
Medicare services
Top 13% in NY for endocrinology
1,287
Unique beneficiaries
$54
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~310 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 2,709 | $18 | $50 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,030 | $116 | $275 |
| Nursing facility visit, low complexity A daily follow-up visit for an existing patient in a nursing facility involving straightforward medical decision making. The visit requires at least 15 minutes of time if time is used to determine the level of care. |
411 | $68 | $275 |
| Initial nursing facility care, moderate complexity Initial care provided to a patient in a nursing facility with moderate medical decision making, taking at least 35 minutes. |
300 | $122 | $300 |
| Continuous glucose monitoring with interpretation This procedure involves monitoring blood sugar levels in tissue fluid using a sensor placed under the skin, along with the interpretation and reporting of the results. |
233 | $31 | $150 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
159 | $58 | $100 |
| Remote patient monitoring management, 20 min/month Management based on results from remote vital sign monitoring for the first 20 minutes per calendar month. |
143 | $45 | $100 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
124 | $13 | $150 |
| Remote patient monitoring device, 30 days Initial setup of devices for remote monitoring of body functions with daily data transmission or alerts. This service covers the first 30 days of the monitoring period. |
92 | $48 | $75 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
89 | $149 | $300 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
85 | $85 | $225 |
| Autonomic nervous system testing with heart rate response to deep breathing This test evaluates the function of the autonomic nervous system by measuring how the heart rate changes in response to deep breathing. |
65 | $83 | $200 |
| Autonomic nervous system function test This test evaluates how well the sympathetic nervous system is functioning. It assesses the automatic control of bodily processes such as heart rate and blood pressure. |
65 | $116 | $300 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
45 | $1 | $50 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
21 | $59 | $75 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
13 | $167 | $300 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$56,101
Total received (2018-2024)
Avg $8,014/year across 7 years
Top 9% in NY for endocrinology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
62
Companies
1,095
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$26,882 (47.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$19,440 (34.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,779 (17.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$9,221
2023
$10,240
2022
$4,342
2021
$2,664
2020
$6,403
2019
$11,842
2018
$11,389
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amneal Pharmaceuticals LLC
$5,708
Xeris Pharmaceuticals, Inc.
$527
Lilly USA, LLC
$450
Novo Nordisk Inc
$432
Boehringer Ingelheim Pharmaceuticals, Inc.
$270
SANOFI-AVENTIS U.S. LLC
$236
Dexcom, Inc.
$196
Corcept Therapeutics
$192
Amgen Inc.
$186
VIVUS LLC
$137
Insulet Corporation
$120
Astellas Pharma US Inc
$85
ABBVIE INC.
$85
Tolmar, Inc.
$68
Mannkind Corporation
$65
Esperion Therapeutics, Inc.
$62
Intra-Sana Laboratories
$55
Abbott Laboratories
$48
BETA BIONICS, INC.
$47
Radius Health, Inc.
$44
Bayer Healthcare Pharmaceuticals Inc.
$30
Medtronic, Inc.
$29
Currax Pharmaceuticals LLC
$28
Sumitomo Pharma America, Inc.
$27
Tandem Diabetes Care, Inc.
$26
IBSA Pharma Inc.
$23
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$23
Verity Pharmaceuticals Inc.
$23
Top 3 companies account for 72.5% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$19,656
SANOFI-AVENTIS U.S. LLC
$9,064
Amneal Pharmaceuticals LLC
$6,054
Corcept Therapeutics
$4,297
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,276
Novo Nordisk Inc
$2,117
Lilly USA, LLC
$1,690
Amgen Inc.
$1,278
Xeris Pharmaceuticals, Inc.
$855
Radius Health, Inc.
$823
Mannkind Corporation
$672
Insulet Corporation
$525
ABBVIE INC.
$492
Dexcom, Inc.
$483
Merck Sharp & Dohme Corporation
$447
Senseonics, Incorporated
$420
Abbott Laboratories
$362
VIVUS LLC
$327
Endo Pharmaceuticals Inc.
$319
MannKind Corporation
$316
Horizon Therapeutics plc
$306
Amarin Pharma Inc.
$241
AbbVie Inc.
$233
Medtronic, Inc.
$221
Shire North American Group Inc
$199
Currax Pharmaceuticals LLC
$197
VIVUS, Inc.
$169
Janssen Pharmaceuticals, Inc
$145
AbbVie, Inc.
$140
IBSA Pharma Inc.
$140
Eisai Inc.
$129
Esperion Therapeutics, Inc.
$126
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$121
Tandem Diabetes Care, Inc.
$113
UROVANT SCIENCES INC
$100
Medtronic MiniMed, Inc.
$98
EISAI INC.
$97
Astellas Pharma US Inc
$85
Tolmar, Inc.
$68
Merck Sharp & Dohme LLC
$67
VistaPharm, Inc.
$57
Intra-Sana Laboratories
$55
Regeneron Healthcare Solutions, Inc.
$53
BETA BIONICS, INC.
$47
Amryt Pharma Holdings Ltd
$40
CeQur Corporation
$37
Clarus Therapeutics Inc.
$32
Bayer Healthcare Pharmaceuticals Inc.
$30
Antares Pharma, Inc.
$30
Sumitomo Pharma America, Inc.
$27
Alexion Pharmaceuticals, Inc.
$24
LifeScan, Inc.
$24
Verity Pharmaceuticals Inc.
$23
Edwards Lifesciences Corporation
$23
Novartis Pharmaceuticals Corporation
$22
Ascensia Diabetes Care US Inc.
$20
Azurity Pharmaceuticals, Inc.
$18
Gilead Sciences, Inc.
$16
Acerus Pharmaceuticals Corporation
$16
Echosens North America, Inc.
$15
Acella Pharmaceuticals, LLC
$15
Gemini Laboratories, LLC
$11
Top 3 companies account for 62.0% of all-time payments
Associated products mentioned in payments ›
AFREZZA · AVEED · Adthyza · BAQSIMI · BASAGLAR · BYDUREON · Belviq · CONTRAVE · CYCLOSET · CardioMEMS HF System · CeQur Simplicity · Corlanor · Dexcom G6 Transmitter · EDEX · ENTRESTO · EVENITY · Edwards SAPIEN 3 Transcatheter Heart Valve · Eversense · FARXIGA · FORTEO · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FibroScan · FreeStyle Libre · FreeStyle Libre 2 · GEMTESA · GVOKE HYPOPEN · GVOKE PFS · INVOKANA · InPen · JANUVIA · JARDIANCE · JATENZO · Kerendia · Korlym · LICART · LYUMJEV · MINIMED 770G · MINIMED 780G · MOUNJARO · MYCAPSSA · Minimed 670G System · Minimed 770G System · NASCOBAL · NATPARA · NATPARA (PARATHYROID HORMONE) · NEXLETOL · NOCDURNA · NP Thyroid 60 · Natesto · OTREXUP · Omnipod · OneTouch Verio Reflect · Ozempic · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Prolia · QSYMIA · QULIPTA · Qsymia · RAYOS · RECORLEV · RELTONE 200 MG · RYBELSUS · Repatha · Rybelsus · SOLIQUA · SOLIQUA 100/33 · STEGLATRO · STEGLUJAN · STRENSIQ · SYNJARDY · SYNTHROID · Saxenda · Synthroid · TEPEZZA · TESTOPEL · TOUJEO · TRADJENTA · TRULICITY · TZIELD · Thyquidity · Tirosint · Tlando · Tresiba · Tymlos · UBRELVY · UNITHROID · VERQUVO · Vascepa · Veozah · Victoza · Wegovy · XARELTO · XIAFLEX · ZEPBOUND · iLet Bionic Pancreas · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ · t:slim X2 insulin pump
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (48%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in endocrinology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 9% for endocrinology in NY.
Geographic Context
Endocrinologists within 10 mi
467
Per 100K population
33.6
County median income
$143,408
Nearest hospital
PLAINVIEW HOSPITAL
3.5 mi
3.5 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Khalfin is a clinical cardiology specialist, with above-average Medicare volume (top 13% in NY), with speaking/promotional industry engagement in the top 9% of NY peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Khalfin experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Khalfin performed 2,709 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Khalfin receive payments from pharmaceutical companies?
Yes. Dr. Khalfin received a total of $56,101 from 62 companies across 1,095 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Khalfin's costs compare to other endocrinologists in Syosset?
Dr. Khalfin's average Medicare payment per service is $54. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Khalfin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Endocrinology
Common procedures, typical costs, and what industry payments mean in endocrinology.
Same specialty & city
Endocrinologists in Syosset
Browse endocrinologists in Syosset ranked by procedure volume and transparency data.
Highest volume
Top Endocrinologists in NY
Endocrinologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Endocrinologists in NY
Which NY endocrinologists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
SANOFI-AVENTIS U.S. LLC Payments to Doctors
See all physicians who received payments from SANOFI-AVENTIS U.S. LLC.
By company
Amneal Pharmaceuticals LLC Payments to Doctors
See all physicians who received payments from Amneal Pharmaceuticals LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology